The Impact of Innovative Biologic Drugs in the Management of Psoriatic Patients
[1]
Alessandra Bettiol, Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
[2]
Roberta Pirolo, Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy; Local Health Authority No. 9, Treviso, Italy.
[3]
Jenny Bolcato, Local Health Authority No. 9, Treviso, Italy.
[4]
Giulia Franchin, Local Health Authority No. 9, Treviso, Italy.
[5]
Paola Deambrosis, Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
[6]
Pietro Giusti, Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
[7]
Alessandro Chinellato, Local Health Authority No. 9, Treviso, Italy.
Severe Psoriasis, Immune-Mediated Comorbidities, Biologic Drugs, Inflammatory Parameters
[1]
Nevitt GJ, Hutchinson PE. Psoriasis in the community; prevalence, severity and patients’ beliefs and attitudes toward the disease. Br J Dermatol. 1996;135(4):533-537.
[2]
Lebwohl M, Menter A, Koo J, Feldman SR. Combination therapy to treat moderate to severe psoriasis. Journal of the American Academy of Dermatology. 2004;50(3):416-430.
[3]
Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol. 2003;4(7):441-447.
[4]
Ciocon DH, Kimball AB. Psoriasis and psoriatic arthritis: separate or one and the same? Br J Dermatol. 2007;157(5):850-860.
[5]
Armstrong AW, Voyles SV, Armstrong EJ, Fuller EN, Rutledge JC. A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis. Exp Dermatol. 2011;20(7):544–549.
[6]
Armstrong AW, Voyles SV, Armstrong EJ, Fuller EN, Rutledge JC. Angiogenesis and oxidative stress: common mechanisms linking psoriasis with atherosclerosis. J Dermatol Sci. 2011;63(1):1–9.
[7]
Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. Journal of the American Heart Association. 2013;4(2):e000062.
[8]
Boehncke WH, Sterry W. Psoriasis - a systemic inflammatory disorder: clinic, pathogenesis and therapeutic perspectives. J Dtsch Dermatol Ges. 2009;7(11):946-952.
[9]
Traub M, Marshall K. Psoriasis - Pathophysiology, Conventional, and Alternative Approaches to Treatment. Alternative Medicine Review. 2007;12(4): 319-330.
[10]
Hazard E, Cherry SB, Lalla D, Woolley JM, Wilfehrt H, Chiou CF. Clinical and economic burden of psoriasis. Manag Care Interface. 2006;19(4):20–26.
[11]
Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383-592.
[12]
Vena GA, Cassano N. Drug focus: adalimumab in the treatment of moderate to severe psoriasis. Biologics: Targets & Therapy. 2007;1(2):93-103.
[13]
Saraceno R, Mannheimer R, Chimenti S. Regional distribution of psoriasis in Italy. J Eur Acad Dermatol Venereol. 2008;22(3):324-329.
[14]
Griffiths CEM, Camp RDB, Barker JNWN. Psoriasis. In: Burns DA, Breathnach SM, Cox N, Griffiths CE eds. Rook’s Textbook of Dermatology. 7th edn. Oxford: Blackwell. 2005;35.1-35.69.
[15]
Rajendran CP, Ledge SG, Rani KP, Madhavan R. Psoriatic Arthritis. J Assoc Physicians India. 2003;51(11):1065-1068.
[16]
Hägg D, Eriksson M, Sundström A, Schmitt-Egenolf M. The Highest Proportion of Men with Psoriasis Treated with Biologics May Be Explained by More Severe Disease in Men. 2013. http://www.plosone.org 8(5) e63619.
[17]
Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Maradit Kremers H. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. J Am Acad Dermatol. 2009;60(3):394-401.
[18]
Tollefson MM, Crowson CS, McEvoy MT, Maradit Kremers H. Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol. 2010;62(6):979-987.
[19]
Lebwohl M, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871-881.
[20]
McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol. 1978;99(5):469-475.
[21]
Gottlieb AB, Dann F. Comorbidities in patients with psoriasis. Am J Med. 2009;122(12):1150 e1-9.
[22]
Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 1997;100(9):2153-2157.
[23]
Kim N, Thrash B, Menter A. Comorbities in psoriatic patients. Semin Cutan Med Surg. 2010;29(1): 10-15.
[24]
Wu JJ, Nguyen TU, Poon KY, Herrinton LJ. The association of psoriasis with autoimmune diseases. J Am Acad Dermatol. 2012;67(5):924-930.
[25]
Lee FI, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with Crohn’s disease and their relatives. Am J Gastroentereol. 1990;85:962-963.
[26]
Makredes M, Robinson D, Bala M, Kimball AB. The burden of autoimmune disease: A comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis. J Am Acad Dermatol. 2009;61(3):405-410.
[27]
Najaran DJ, Gottlieb AB. Connections between psoriasis and Crohn’s disease. J Am Acad Dermatol. 2003;48:805-821.
[28]
Busard C, Zweegers J, Limpens J. Combined used of systemic agents for psoriasis- a systematic review. JAMA Dermatology. 2014;150(11):1213-1220.Bardenheier B, Wortley PM, Ahmed F, Gravenstein S, Hogue CR. Racial inequities in receipt of influenza vaccination among long-term care residents within and between facilities in Michigan. Med Care 2011;49:371-7.
